After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We have now added a new section called the "Assay History List" to the "At A Gla...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...